---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Contraindications/Warnings/Precautions/Adverse effects"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Contraindications/Warnings/Precautions/Adverse effects. Covers Warnings and precautions. 29 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/contraindications-warnings-precautions-adverse-effects"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Contraindications/Warnings/Precautions/Adverse effects

<a id="heading-2.1.2.7"></a>

## 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

#### FDA-approved prescribing information for Barzolvolimab

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

#### Adverse events through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “Adverse Events Through 24 Week Placebo Controlled Period (AEs observed in > 3% of patients)”
> “Pooled EMBARQ-CSU1 and EMBARQ-CSU2”
> “On barzolvolimab, the vast majority of AEs are mild to moderate”
> “Rate of SAEs similar across treatment groups”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Adverse event, n (%) | Placebo Q4W | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W |
| --- | --- | --- | --- |
| Participants (N) | “N=645” | “N=648” | “N=641” |
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

> “Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior experience through the end of the placebo controlled period at Week 24.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.2.7.1-3"></a>

#### Anaphylaxis adjudication through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “Adverse Events Through 24 Week Placebo Controlled Period (AEs observed in > 3% of patients)”
> “Pooled EMBARQ-CSU1 and EMBARQ-CSU2”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Anaphylaxis | Placebo Q4W | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W |
| --- | --- | --- | --- |
| Participants (N) | “N=645” | “N=648” | “N=641” |
| Adjudicated as probable (G4) | “0” | “2” | “1 (occurred after placebo dose)” |
| Other (events in the footnotes below) | “1” | “1” | “3” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

> “G3 anaphylaxis adjudicated as unlikely”
> “G2 angioedema/throat tightness/urticaria”
> “G3 anemia/neutropenia;”
> “G2 malaise/dyspnea/chest pain;”
> “G3 anaphylaxis after placebo administration”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.2.7.1-4"></a>

#### Anaphylaxis adjudication: phase 2 in cold urticaria and symptomatic dermographism

> “Here we report the primary analysis (Week 12) of a Phase 2 study evaluating the efficacy and safety of barzolvolimab compared with placebo in patients with cold urticaria and symptomatic dermographism whose disease is inadequately controlled by antihistamines (NCT05405660)”
> “Single treatment related SAE (anaphylaxis) reviewed by independent expert adjudication panel who concluded there was no evidence of anaphylaxis”

Source: [Maurer et al. (2024e)](https://celldex.com/wp-content/uploads/2025/06/Barzolvolimab_Phase-2-ClndU_ACAAI_FINAL.pdf)

<a id="topic-2.1.2.7.1-5"></a>

#### Anaphylactic reaction: prurigo nodularis phase 1b, 3.0 mg/kg intravenous dose

> “We have expanded clinical development of barzolvolimab into prurigo nodularis (PN).”
> “We have completed a Phase 1b multi-center, randomized, double-blind, placebo-controlled intravenous study in PN.”
> “During the initial 8 week observation period in the 3.0 mg/kg dosing arm, an anaphylactic reaction occurred in a complicated patient with multiple comorbidities; the event fully resolved without sequelae.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.7.1-6"></a>

#### Neutropenia and infection rates: phase 3

> “Barzolvolimab Did Not Lead to Increased Rate of Infections”
> “No increased rates of infection in barzolvolimab vs placebo treatment groups”
> “Placebo: 23.9%”
> “150 mg Q4W: 24.4%”
> “300 mg Q8W: 23.6%”
> “Rates of neutropenia in Phase 3 were consistent with Phase 2”
> “Placebo: 0.6%”
> “150 mg Q4W: 9.1%”
> “300 mg Q8W: 11.7%”
> “Neutropenia Not Associated with Increased Incidence of Infections”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.2.7.1-7"></a>

#### Hematologic laboratory decreases: phase 1b intravenous dosing in chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks”
> “Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.”
> “The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections. Decreases in hematologic parameters were consistent with observations in healthy volunteers [10] and patients with chronic inducible urticaria [7] who received a single barzolvolimab dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-8"></a>

#### Hair color and skin pigmentation changes: phase 2 through Week 76

> “The objective of this analysis was to assess the rate and reversibility of pigmentation changes over 76 weeks in patients with CSU treated with barzolvolimab”
> “204 patients received ≥1 dose of barzolvolimab (any dose) and were included in this analysis”
> “Hair color changes (hypopigmentation) occurred in 49 (24%) patients; 96% of hair color changes were mild (Grade 1). Mean time to onset was ≈4 months, with 91% of evaluable patients reporting resolution of hair color change by the end of study participation”
> “Skin hypopigmentation occurred in 36 (18%) patients and events were mostly mild (94%; Grade 1); mean onset was ≈9 months, with 68% of evaluable patients reporting resolution by data cutoff”
> “Skin hyperpigmentation occurred in 6 (3%) patients, all of whom reported the events as mild (Grade 1); mean time to onset was ≈5 months, with 67% of evaluable patients reporting resolution by data cutoff”
> “Overall, 19 (9%) of patients reported concomitant hair color changes and skin hypopigmentation; 4 (2%) reported hair color changes and concomitant skin hyperpigmentation”
> “KIT-mediated hair color and skin pigmentation changes were observed in a subset of patients and were generally mild and reversible”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

| Characteristic | Hair color changes | Skin hypopigmentation | Skin hyperpigmentation |
| --- | --- | --- | --- |
| Participants with the event | “n=49” | “n=36” | “n=6” |
| Grade 1, n (%) | “47 (96)” | “34 (94)” | “6 (100)” |
| Time to onset from start of barzolvolimab, days, mean (range) | “137 (7-397)” | “271 (107-424)” | “156 (11-283)” |
| Resolved at the time of data cutoff, n (%) | “40 (91)” | “19 (68)” | “4 (67)” |
| Time to resolution on treatment, days, median (95% CI) | “209 (119, 231)” | “110 (60, 120)” | “25 (7, NE)” |
| Time to resolution off treatment, days, median (95% CI) | “168 (138,189)” | “214 (196, 285)” | “NE” |
| Discontinued study treatment due to event, n (%) | “6 (3)” | “0 (0)” | “1 (<0.5)” |

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-2.1.2.7.1-9"></a>

#### Hair color changes: chronic inducible urticaria phase 1b

> “This is an ongoing single center, open-label Phase 1b study evaluating the safety/tolerability and clinical efficacy of a single dose of barzolvolimab in patients with CIndU refractory to SG-H1AHs.”
> “First appearance of hair color change was reported 4–6 weeks post-treatment. Affected areas were mainly head hair, eyebrows, eyelashes and in men beard hair as well as body hair in some patients. The hair color change was transient and improved over time with new hair growth at about 10–12 weeks post-treatment, with complete resolution over time during a follow-up. Overall, the hair color changes were considered mild and not burdensome to patients.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.7.1-10"></a>

#### Taste changes: chronic inducible urticaria phase 1b

> “This is an ongoing single center, open-label Phase 1b study evaluating the safety/tolerability and clinical efficacy of a single dose of barzolvolimab in patients with CIndU refractory to SG-H1AHs.”
> “Taste changes include ageusia and hypogeusia.”
> “Taste changes were reported by patients as being selective for umami and salty flavor. All patients experiencing taste changes reported the ability to taste, but less intensively and the loss of intensity varied between patients. Changes were all transient and improved gradually with complete resolution within 12 weeks after treatment in most patients. Given the quick resolution, patients did not report impairment of quality of life by the taste changes.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.7.1-11"></a>

#### Taste changes: phase 1b in chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “Taste changes, as noted in prior barzolvolimab studies, were reported by three patients (< 10%).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-12"></a>

#### Infections: phase 1b in chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “A total of 40% of barzolvolimab‐treated patients and 20% of placebo‐treated patients experienced an infection AE. The infections that were reported by > 10% of barzolvolimab‐treated patients were COVID‐19 (14%), nasopharyngitis (11%), and UTI (11%), and were not correlated with neutrophil decreases.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-13"></a>

#### Treatment discontinuations for adverse events: phase 2 through Week 52

> “Patient Disposition Through 52 Weeks”
> “Placebo and 75mg Q4W re-randomized to 150mg Q4W or 300mg Q8W at Week 16”
> “Adverse event discontinuations in more than one patient: hair color changes (6), urticaria (5), macrocytic anemia (2)”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

| Disposition, n (%) | Barzolvolimab 75 mg Q4W, then 150 mg or 300 mg | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W | Placebo, then barzolvolimab 150 mg or 300 mg |
| --- | --- | --- | --- | --- |
| Randomized | “n=53” | “n=52” | “n=52” | “n=51” |
| Discontinued treatment | “13 (25%)” | “13 (25%)” | “13 (25%)” | “8 (16%)” |
| Discontinued for an adverse event | “7 (13%)” | “4 (8%)” | “7 (13%)” | “2 (4%)” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Discontinuation due to pigmentation changes was low (hair color changes: 3%, n=6; skin hypopigmentation, n=0; skin hyperpigmentation: <0.5%, n=1 )”
> “Discontinuations due to pigmentation changes were uncommon, suggesting these changes were tolerable for patients”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-2.1.2.7.1-14"></a>

#### Reversibility off treatment: phase 2 follow-up to Week 76

> “Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. No new safety signals were identified during the follow-up period. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Here we present the efficacy and safety of barzolvolimab during the 24-week follow up period”
> “Barzolvolimab was well tolerated with no new safety findings identified during follow up period”
> “These events were generally mild (grade 1), KIT-mediated and reversible”
> “Neutropenia/neutrophil count events resolved while on treatment and were not associated with infection”
> “Resolution of hair color changes and skin hypopigmentation observed following discontinuation of treatment”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="topic-2.1.2.7.1-15"></a>

#### Reversibility off treatment: chronic inducible urticaria phase 1b follow-up through Week 36

> “Long term follow up data was collected from the 3.0 mg/kg cohorts in cold urticaria and symptomatic dermographism.”
> “Data were collected at one or more timepoints beyond Week 12 through Week 36.”
> “Drug related adverse events noted during the study all resolved.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.7.1-16"></a>

#### Phase 2 adverse events through Week 12

> “We have completed a Phase 2 study in patients with CSU who remained symptomatic despite antihistamine therapy.”
> “Barzolvolimab was well tolerated with a favorable safety profile. Most adverse events were mild to moderate in severity; through 12 weeks, the most common treatment emergent adverse events in barzolvolimab treated patients were urticaria/CSU (10%), hair color changes (9%), and neutropenia/ANC decrease (8%). The rate of infections was similar between barzolvolimab treated patients and placebo with no association between neutropenia and infections.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.7.1-17"></a>

#### Phase 2 most common adverse events across doses

> “Adults with antihistamine-refractory CSU (urticaria activity score over 7 days [UAS7] ≥ 16) in a phase 2 double-blind placebo-controlled trial were randomized 1:1:1:1 to receive barzolvolimab 75 mg every 4 weeks (n = 53); 150 mg every 4 weeks (n = 52); 300 mg every 8 weeks (n = 51); or placebo (n = 51).”
> “All doses of barzolvolimab were well tolerated, with urticaria and hair color change as the most common adverse events in barzolvolimab-treated patients.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-2.1.2.7.1-18"></a>

#### Phase 2 adverse events: placebo-controlled period to Week 16 and treatment period to Week 52

> “Barzolvolimab was well tolerated through 52 weeks of treatment”
> “Placebo Controlled Period (16 weeks)”
> “All dose levels (75mgQ4W, 150mgQ4W, 300mgQ8W) combined”
> “All dose levels combined; patients randomized to 75mgQ4W were re-randomized to 150mgQ4W or 300mgQ8W at week 16”
> “Patients received 36 weeks of barzolvolimab 150mgQ4W or 300mgQ8W after 16 weeks of placebo; data are shown for 36 week barzolvolimab experience”
> “SAEs of worsening urticaria symptoms”
> “Most events were grade 1 (mild), mechanism-related (KIT) and expected to be reversible”
> “Adverse events were not dose dependent”
> “No association between infections and neutropenia/decreased neutrophil counts”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

| Participants, n (%) | Barzolvolimab, all doses, Weeks 0 to 16 | Placebo, Weeks 0 to 16 | Barzolvolimab, all doses, Weeks 0 to 52 | Placebo then barzolvolimab, 36 weeks of barzolvolimab |
| --- | --- | --- | --- | --- |
| Participants (N) | “N= 156” | “N= 51” | “N= 156” | “N=48” |
| At least one adverse event | “103 (66)” | “20 (39)” | “139 (89)” | “32 (67)” |
| Treatment-related serious adverse events | “0” | “0” | “2 (1)” | “0” |
| Hair color changes | “22 (14)” | “0” | “40 (26)” | “8 (17)” |
| Neutropenia or neutrophil count decreased | “14 (9)” | “0” | “26 (17)” | “2 (4)” |
| Urticaria | “15 (10)” | “5 (10)” | “23 (15)” | “3 (6)” |
| Skin hypopigmentation | “2 (1)” | “0” | “21 (13)” | “9 (19)” |
| Nasopharyngitis | “6 (4)” | “3 (6)” | “15 (10)” | “4 (8)” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Barzolvolimab was well tolerated with a favorable safety profile through 52 weeks of treatment. Most adverse events were grade 1 (mild), mechanism related (KIT) and expected to be reversible. The most common treatment emergent adverse events occurring in greater than 10% of barzolvolimab treated patients were hair color changes, neutropenia, urticaria, skin hypopigmentation (areas of skin lightening) and nasopharyngitis (common cold). Neutrophil counts did not decline further with continued dosing and there was no association between infections and neutropenia. The hypopigmentation was observed with longer term exposure and did not lead to treatment discontinuation. Adverse events were not dose dependent.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.7.1-19"></a>

#### Phase 1b adverse events at 24 weeks: intravenous dosing in chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks”
> “TEAEs reported by system organ class and preferred term in ≥ 10% barzolvolimab‐treated patients at 24 weeks.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

| Treatment-emergent adverse event, n (%) | All barzolvolimab | Pooled placebo |
| --- | --- | --- |
| Participants (N) | “N = 35” | “N = 10” |
| Any treatment-emergent adverse event | “30 (86)” | “6 (60)” |
| Neutropenia | “5 (14)” | “0 (0)” |
| Leukopenia | “3 (9)” | “0 (0)” |
| Headache | “5 (14)” | “2 (20)” |
| Hair color changes | “9 (26)” | “0 (0)” |

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “Overall, 30 barzolvolimab‐treated patients (86%) and 6 placebo‐treated patients (60%) experienced a TEAE. In the 1.5‐mg/kg group, two barzolvolimab‐treated patients (6%) experienced infusion‐related TEAEs. One patient (3%) in the 3.0‐mg/kg group experienced a TEAE that led to drug interruption. No patients experienced a dose‐limiting toxicity or any TEAE that led to treatment discontinuation.”
> “Hair color change was the most common event, experienced by nine barzolvolimab‐treated patients (26%; Table 2); hair color changes occurred in different locations: scalp, beard, and body hair; and seven patients had this TEAE resolve by the end of the study.”
> “Most AEs were mild or moderate in severity and resolved while on study. One SAE of Grade 4 salmonella gastroenteritis in a 59‐year‐old Black woman (1.5‐mg/kg group) was assessed by the investigator as unrelated to study treatment; she was treated with Levaquin, was discharged, and completed the study as planned.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-20"></a>

#### Immunogenicity: antidrug antibodies in phase 1b chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.”
> “Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.”
> “Antibarzolvolimab antibodies did not appear to impact the safety parameters in this study.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-21"></a>

#### Immunogenicity: antidrug antibody status and exposure after a single intravenous dose in prurigo nodularis

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Adults with moderate-to-severe PN were randomly assigned in a 1:1:1 ratio to placebo or barzolvolimab at 1.5 or 3.0 mg/kg as an intravenous infusion and were followed for 24 weeks.”
> “Exposure was not influenced by intrinsic and extrinsic participant-specific parameters, including sex, weight, or treatment-emergent antidrug antibody status”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.7.1-22"></a>

#### Immunogenicity: risk factor text on antibodies against biologics

> “In addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by our product candidates, the administration of biologics frequently causes an immune response, sometimes resulting in the creation of antibodies against the drug candidate which can impact the safety and/or efficacy associated with the treatment.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.7.1-23"></a>

#### Chronic inducible urticaria phase 1b: single 3 mg/kg intravenous dose

> “This is an ongoing single center, open-label Phase 1b study evaluating the safety/tolerability and clinical efficacy of a single dose of barzolvolimab in patients with CIndU refractory to SG-H1AHs.”
> “Single dose of barzolvolimab is administered intravenously on Day 1, and patients are followed for 12 weeks for safety, PD, and clinical activity assessments.”
> “Here, we report data from two cohorts of patients with ColdU and SD treated with a single dose of barzolvolimab (3 mg/kg) followed for 12 weeks as detailed below.”
> “Barzolvolimab was well tolerated (Table 2). All 21 patients reported AE. Most AEs were mild, and the most common (≥3 patients) were hair color changes (areas of hair lightening) (76%; n = 16/21), infusion reactions (43%; n = 9/21), taste changes (38%; n = 8/21), nasopharyngitis (24%; n = 5/21), malaise (24%; n = 5/21), and headache (19%; n = 4/21).”
> “Infusion reactions, which manifested as localized hives and itching as well as erythema and feeling hot, resolved spontaneously. One patient with a history of fainting experienced loss of consciousness during infusion; this event was not associated with MC activation based on decreasing tryptase values shortly after the event.”
> “Overall, mean hematology parameters remained within the normal ranges. Mild, transient, and asymptomatic decreases in hemoglobin and white blood cell parameters occurred for some patients (Figure S1).”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.7.1-24"></a>

#### Chronic inducible urticaria phase 2: Week 12 and Week 20 treatment periods

> “We completed a Phase 2 study in patients with CIndU who remain symptomatic despite antihistamine therapy.”
> “Barzolvolimab was well tolerated with a favorable safety profile consistent with prior studies. Most adverse events were grade 1 (mild). Through 12 weeks, the most common treatment emergent adverse events in barzolvolimab treated patients were hair color changes (13%; Grade 1, n=15 / Grade 2, n=2) and neutropenia (10%; Grade 1, n=7 / Grade 2, n=6), which are mechanism related (KIT) and expected to be reversible. The rate of infections was similar between barzolvolimab-treated patients and placebo with no association between neutropenia and infections.”
> “Barzolvolimab was well tolerated with a favorable safety profile over the 20 week treatment period consistent with previous studies. There was no difference between active treatment (2%) and placebo groups (3%) in rate of discontinuations due to adverse events. Most adverse events for patients on study drug were grade 1 (mild), mechanism related (KIT) and, as demonstrated in previous studies, expected to be reversible. The most common adverse events occurring in greater than 10% of patients in any treatment group through Week 20 were hair color changes (18%; Grade 1, n=22 / Grade 2, n=2) and neutropenia (12%; Grade 1, n=9 / Grade 2, n=6). Neutropenia was transient and there was no association with infections.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Here we report the primary analysis (Week 12) of a Phase 2 study evaluating the efficacy and safety of barzolvolimab compared with placebo in patients with cold urticaria and symptomatic dermographism whose disease is inadequately controlled by antihistamines (NCT05405660)”
> “98% of treatment emergent adverse events were Grade 1 or 2 (mild (66.7%), moderate (31.7%))”
> “Other discontinuations due to AEs: urticaria/lip edema (150mg), neutropenia (300mg), cystic acne/aphthous ulcer (placebo) and paraesthesia oral/swollen tongue (placebo)”

Source: [Maurer et al. (2024e)](https://celldex.com/wp-content/uploads/2025/06/Barzolvolimab_Phase-2-ClndU_ACAAI_FINAL.pdf)

| Participants, n (%) | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W | All barzolvolimab | Placebo |
| --- | --- | --- | --- | --- |
| Participants (n) | “n=65” | “n=65” | “n=130” | “n=63” |
| Any adverse event | “40 (62%)” | “39 (60%)” | “79 (61%)” | “33 (52%)” |
| Treatment-related serious adverse events | “0” | “1 (2%)” | “1 (1%)” | “0” |
| Discontinued study treatment for adverse events | “1 (2%)” | “2 (3%)” | “3 (2%)” | “2 (3%)” |
| Hair color changes | “9 (14%)” | “8 (12%)” | “17 (13%)” | “0” |
| Neutropenia | “4 (6%)” | “9 (14%)” | “13 (10%)” | “0” |

Source: [Maurer et al. (2024e)](https://celldex.com/wp-content/uploads/2025/06/Barzolvolimab_Phase-2-ClndU_ACAAI_FINAL.pdf)

<a id="topic-2.1.2.7.1-25"></a>

#### Prurigo nodularis: adverse events after a single intravenous dose

> “Adults with moderate-to-severe PN were randomly assigned in a 1:1:1 ratio to placebo or barzolvolimab at 1.5 or 3.0 mg/kg as an intravenous infusion and were followed for 24 weeks.”
> “Treatment-emergent adverse events were reported in 5/8 (62.5%) placebo-treated participants and 6/15 (40.0%) barzolvolimab-treated participants. Treatment-emergent adverse events were mild or moderate and resolved while on study”
> “A single intravenous dose of barzolvolimab 3.0 mg/kg was well tolerated and led to a meaningful reduction in itch, improved lesion healing, and decreased serum tryptase in patients with moderate-to-severe PN.”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.7.1-26"></a>

#### Prurigo nodularis phase 2: 450 mg loading dose then 150 or 300 mg every 4 weeks

> “This Phase 2 randomized, double-blind, placebo-controlled, parallel group study evaluated barzolvolimab compared to placebo in patients with moderate to severe PN who had inadequate response to prescription topical medications, or for whom topical medications were medically inadvisable.”
> “140 patients were randomly assigned to receive barzolvolimab 150mgQ4W after an initial loading dose of 450mg, 300mgQ4W after an initial loading dose of 450mg, or placebo during a 24-week Treatment Phase.”
> “Barzolvolimab was well tolerated. Loading dose (450mg) followed by Q4W dosing (150 or 300mg) demonstrated favorable safety profile consistent with prior studies.”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

<a id="topic-2.1.2.7.1-27"></a>

#### Eosinophilic esophagitis phase 2: 300 mg every 4 weeks through Week 44

> “today reported topline results from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.”
> “65 patients were randomly assigned on a 1:1 ratio to receive subcutaneous injections of barzolvolimab at 300 mg every 4 weeks or placebo during a 16-week placebo-controlled treatment phase.”
> “Barzolvolimab demonstrated a favorable safety profile at the 300 mg Q4 weekly dosing regimen, consistent with prior studies where barzolvolimab was dosed less frequently.”
> “An unblinded review of all available data through the full treatment period (28 weeks) and full study (44 weeks) was conducted and clinical and safety outcomes were consistent at these timepoints.”

Source: [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)

<a id="topic-2.1.2.7.1-28"></a>

#### Healthy volunteers: single intravenous doses of 0.3 to 9 mg/kg

> “placebo‐controlled phase 1a healthy volunteer study of CDX‐0159”
> “A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1). A CDX‐0159 intravenous infusion was well tolerated at all doses. The most common adverse event (AE)s observed in thirteen out of twenty‐four subjects who received CDX‐0159 were mild, self‐limited infusion reactions that were consistently described as areas of local itching associated with erythema, and induration/hives, which started during the infusions (Table 2).”
> “Mild decreases in hemoglobin levels generally within the normal range were observed, which rapidly stabilized despite the presence of high plasma drug levels (Figure 3A).”
> “In addition, all CDX‐0159 treatment groups showed variable, asymptomatic decreases relative to placebo on circulating neutrophils, which were also reflected in the total leukocyte count and did not further decline during the course of the study (Figure 3B,C).”
> “In our healthy volunteer study, there were no reports of hair color changes.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

| Treatment-emergent adverse event, n (%) | CDX-0159, all doses | Placebo |
| --- | --- | --- |
| Participants (n) | “Total (n = 24)” | “Placebo (n = 8)” |
| Any event | “19 (79%)” | “5 (63%)” |
| Infusion-related reaction | “13 (54%)” | “0 (0%)” |
| White blood cell count decreased | “4 (17%)” | “1 (13%)” |
| Neutrophil count decreased | “4 (17%)” | “1 (13%)” |
| Sensation of foreign body in the throat | “3 (13%)” | “0 (0%)” |

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.7.1-29"></a>

#### Healthy volunteers: single ascending subcutaneous doses

> “A randomized, double-blind, placebo-controlled, Phase 1 study designed to evaluate the safety of single ascending doses of the subcutaneous formulation of CDX-0159 has been conducted in healthy volunteers. Subcutaneous administration of CDX-0159 demonstrated a well tolerated safety profile; no injection site reactions were reported.”

Source: [Celldex fourth quarter 2021 results release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-full-year-2021-financial)

<a id="topic-2.1.2.7.1-30"></a>

#### Risk factor text on hypersensitivity, anaphylaxis, and injection-site reactions

> “Our drug candidates, including barzolvolimab, are monoclonal antibodies, which are biologics. Side effects from biologics may include but are not limited to hypersensitivity; severe reactions such as anaphylaxis or cytokine release syndrome; immune-mediated adverse reactions that may occur in any organ system or tissue, such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions; as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea.”
> “There are risks inherent in subcutaneous injections, such as injection-site reactions (including redness, itching, swelling, pain, and tenderness) and other side effects.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

Additional sources: [Muñoz et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42206950/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
